In an exploratory, long-term pooled analysis, there was no evidence of cumulative or delayed toxicity with up to 5 years of treatment with IBRANCE in combination with letrozole or IBRANCE in combination with fulvestrant in 1^st line or later¹

Data were pooled from three randomized studies of patients with HR+/HER2− ABC, including postmenopausal women who had not received prior systemic treatment for advanced disease (PALOMA-1/-2) and pre- and postmenopausal women who had progressed on prior ET (PALOMA-3).

With additional follow-up from the Phase II PALOMA-1 and Phase III PALOMA-2 and -3 trials, the safety profile remained consistent and manageable.^2,3

This 5-year analysis demonstrates that IBRANCE plus ET has a consistent and stable safety profile without cumulative or delayed toxicities.